Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

522 Postmarket Surveillance Studies Database
  • Print
  • Share
  • E-mail
-
The FDA has the authority to require device manufacturers to perform postmarket surveillance under Section 522 of the Food, Drugs and Cosmetics (FD&C) Act, when questions are identified for devices that meet the statutory criteria. This database contains information about 522 Postmarket Surveillance Studies that have been required. This database allows you to search information about the postmarket surveillance requirements by manufacturer or device.

Learn more...

            
  To search for Manufacturer beginning with a specific letter, select that letter
 
 A 
 B 
 C 
 D 
 E 
 F 
 G 
 H 
 I 
 J 
 L 
 M 
 N 
 O 
 P 
 R 
 S 
 T 
 U 
 V 
 W 
 X 
 Z 
 
 
   

Prospective Postmarket Surveillance Study Plan


 
Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Progress Inadequate
522 Number / Requirement Number PS110002 / PSS005
Date Original Plan Accepted 02/04/2011
Date Current Plan Accepted 11/14/2016
Study Name Prospective Postmarket Surveillance Study Plan
Device Name Tmj fossa-eminence/condylar prosthesis system
Root Document Number P000023  P000035 
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives Prospective, single-arm, postmarket surveillance descriptive study
Study Population Subjects with a need for implantation of either a TMJ Fossa- Eminence and Condylar Prosthesis System or a TMJ Fossa- Eminence Prosthesis System
Sample Size A first revision rate of 7% at 5 years was used for sample size estimation. For the precision of this estimate, the margin of error for the upper limit of the confidence band was set as 3.5%. If the assumed true proportion is 7%, the sample size required for a 95% 1-tailed error margin of 3.5% is 222 subjects. With allowance for 20% loss to follow-up, 278 subjects for the Total Joint System and 278 subjects for the Partial Joint System will be enrolled.
Key Study Endpoints Primary endpoint: Time to first revision, from which the revision rates will be derived for both the Partial Joint System and the Total Joint System at 1, 2, 3, 4, and 5 years. Secondary endpoint:
• The impact of patient diagnosis on the timeframe to revision
• Time interval (in months) after initial revision to subsequent revisions
• Reasons for initial and subsequent revisions
• Association between patient demographics and/or clinical data and device failure
• Time to revision in which the Revision specifically entails revising the partial implant to a total implant
Follow-up Visits and Length of Follow-up Subjects will be recruited at participating study centers for inclusion in this study from the population of patients who present with severe TMJ disease that meets the criteria for partial or total joint reconstruction outlined in the approved indications for use.
5 years (60 months)


Prospective Postmarket Surveillance Study Plan Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 09/14/2016 09/16/2016 Overdue/Received
1 year report 03/16/2017 03/20/2017 Overdue/Received
18 month report 09/14/2017 02/01/2019 Overdue/Received
2 year report 03/16/2018   Overdue
3 year report 03/16/2019   Overdue
4 year report 03/15/2020   Overdue
5 year report 03/15/2021   Overdue
6 year report 03/15/2022   Overdue
7 year report 03/15/2023   Overdue
8 year report 03/15/2024   Overdue


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources
-
-